Plenary Session - inactive due to federal service

Plenary Session is medical commentary with a clinical trial spine. The show returns again and again to the question of what counts as good evidence, who gets to decide, and what happens when medicine builds policy on weak assumptions. Oncology is the home base. Episodes scrutinize cabozantinib for neuroendocrine tumors, hematology and heme malignancy studies, accelerated approval, surrogate endpoints, systematic reviews, and meta-analysis. But the show does not stay inside the journal article. It follows the money, the agencies, and the politics around the article. NIH grants, study sections, indirect university funding, CDC messaging, FDA standards, HHS leadership, RFK Jr., Anthony Fauci, lab-leak debates, MMR vaccines, DEI, USAID, and academic freedom all become part of the same argument about incentives and accountability. The format is often direct and uncut. A topic is named, the background gets filled in, and then the episode keeps testing the claim from different angles until the judgment is hard to miss. Short lines land between longer technical stretches. That rhythm matters. It lets the show move from randomized trials and endpoint design to blunt institutional criticism without pretending those are separate worlds. The most useful moments come when trial language is made legible: placebo controls, crossover, central versus local review, dose reductions, all-cause endpoints, observational grant analyses, or the hazards of weak meta-analysis. The show can be sharp, sarcastic, and combative. It is also unusually specific. Rather than offering generic trust-the-science reassurance, it asks whether the method, incentive, or institution actually deserves trust in that case. Some episodes are classroom-style lectures, including systematic review instruction and critical appraisal sessions. Others are rapid policy reactions to federal health changes. The result is a show for listeners who want medicine discussed as a contested system, not a press release.